吡非尼酮治疗双肺移植后闭塞性细支气管炎综合征的欧洲多中心随机对照试验
该研究为研究者发起的国际多中心随机双盲安慰剂对照II期试验,纳入90例双肺移植后进展性BOS患者,随机接受吡非尼酮2403 mg·day-1或安慰剂联合标准治疗26周。主要终点FEV1变化在两组均持续下降且无显著差异,次要终点亦相似,提示吡非尼酮不优于安慰剂,不能推荐用于治疗BOS。
要点
- 吡非尼酮2403 mg·day-1治疗26周未改善双肺移植后进展性BOS患者的FEV1。
- 意向治疗、插补及符合方案分析均未显示吡非尼酮优于安慰剂。
- 移植肺丢失、死亡和再移植等次要终点两组相似,不能推荐吡非尼酮治疗BOS。
核心结论
- 吡非尼酮在该探索性试验中未显示优于安慰剂联合标准治疗,不能推荐用于治疗BOS。
研究设计与样本
- 研究者发起的国际多中心随机双盲安慰剂对照II期试验,在9个欧洲肺移植中心开展。
- 纳入双肺移植后进展性BOS成人患者,1:1随机接受吡非尼酮2403 mg·day-1或安慰剂联合标准治疗26周。
- 共筛查477例,随机90例至吡非尼酮组(n=48)或安慰剂组(n=42)。
- 主要终点为基线至第26周FEV1变化,缺失值采用插补法处理。
主要发现
- 两组FEV1从基线至第26周均持续下降,意向治疗、插补意向治疗及符合方案分析均无显著差异。
- 移植肺丢失、死亡和再移植等次要终点两组相似。
- 治疗相关严重不良事件两组分布均衡。
临床怎么用
- 不推荐将吡非尼酮用于治疗双肺移植后进展性BOS。
- 需进一步研究其他CLAD治疗方法以改善肺移植后长期结局。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic lung allograft dysfunction (CLAD) is a major obstacle to improving outcomes after lung transplantation. Bronchiolitis obliterans syndrome (BOS), characterised by progressive decline in forced expiratory volume in 1 s (FEV1) due to fibrotic scarring of the small airways, accounts for most CLAD cases. Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, was assessed for treating progressive BOS. METHODS: An investigator-initiated, international, multicentre, randomised, double-blind, placebo-controlled phase II trial was conducted in nine European lung transplant centres. Adults with bilateral lung transplants and progressive BOS were randomised (1:1) to receive pirfenidone 2403 mg·day-1 or placebo with standard care for 26 weeks. The primary end-point was change in FEV1 from baseline to week 26, with imputation for missing values. FINDINGS: From 1 May 2015 to 1 December 2019, 477 patients were screened, and 90 were randomised to pirfenidone (n=48) or placebo (n=42). Both groups showed continued decline in FEV1 from baseline to week 26, with no significant difference in intention to treat (ITT), ITT with imputation, or per-protocol analyses. Secondary end-points (graft loss, death, re-transplantation) were similar between groups. Treatment-related serious adverse events were distributed equally. INTERPRETATION: Pirfenidone did not show superiority over placebo and standard care in this exploratory trial. It cannot be recommended for treating BOS. Further research is needed to explore other treatments for CLAD to improve long-term outcomes after lung transplantation.
引用
- Perch M, Corris P, Lordan J, et al. A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation. Eur Respir J. 2026. PMID: 41232942. doi:10.1183/13993003.02154-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。